JS207 Combination Therapy in Triple-negative Breast Cancer

NCT07045311 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: JS207 in combination with 9MW2821
DRUG: JS207 in combination with Albumin paclitaxel

Sponsor

Shanghai Junshi Bioscience Co., Ltd.